Table 1 Baseline characteristics of the CNL subgroup
Variables | Total | Recurrence(n = 8) | Non-recurrence(n = 160) | P value |
|---|---|---|---|---|
Clinical and pathological | ||||
 Age (years)(\(\overline{x }\)±s) | 56.11 ± 8.93 | 58.75 ± 11.67 | 55.97 ± 8.80 | 0.393 |
 BMI ((kg/m2)(\(\overline{x }\)±s) | 26.58 ± 3.73 | 26.94 ± 2.05 | 26.56 ± 3.80 | 0.782 |
 Pathological type (n)(%) |  |  |  | 0.035 |
  Endometrioid adenocarcinoma | 159 | 5(71.4) | 154(96.3) |  |
  Non-endometrioid adenocarcinoma | 8 | 2(28.6) | 6(3.8) |  |
 Myometrial invasion (n)(%) |  |  |  | 0.360 |
   < 1/2 | 127 | 4(57.1) | 123(76.9) |  |
   ≥ 1/2 | 40 | 3(42.9) | 37(23.1) |  |
 FIGO (n)(%) |  |  |  | 0.038 |
  Early (stage I–II) | 147 | 4(57.1) | 143(89.4) |  |
  Advanced (stage III–IV) | 20 | 3(42.9) | 17(10.6) |  |
 Grade (n)(%) |  |  |  | 0.062 |
  Low (Grade 1–2) | 153 | 4(66.7) | 149(93.7) |  |
  High (Grade 3) | 12 | 2(33.3) | 10(6.3) |  |
 LVSI (n)(%) |  |  |  | 0.159 |
  Negative | 129 | 4(57.1) | 125(80.1) |  |
  Positive | 34 | 3(42.9) | 31(19.9) |  |
 Cervical invasion (n)(%) |  |  |  | 0.616 |
  No | 152 | 6(85.7) | 146(91.3) |  |
  Yes | 15 | 1(14.3) | 14(8.8) |  |
 Lymph node metastasis (n)(%) |  |  |  | 0.052 |
  No | 155 | 4(66.7) | 151(94.4) |  |
  Yes | 11 | 2(33.3) | 9(5.6) |  |
Immunohistochemistry | ||||
 ER(%)[M(P25,P75)] | 70[50,90] | 10[0,72.5] | 70[50,90] | 0.015 |
 PR(%)[M(P25,P75)] | 75[50,90] | 15[0,50] | 80[50,90] | 0.005 |
 Ki-67(%)[M(P25,P75)] | 30[20,40] | 40[22.5,67.5] | 30[20,40] | 0.158 |
Metabolic indexes | ||||
 FBG(mmol/L)[M(P25,P75)] | 5.8[5.2,6.8] | 5.9[5.2,9.2] | 5.8[5.2,6.8] | 0.582 |
 FINS(uU/ml)[M(P25,P75)] | 12.9[7.7,12.9] | 12.9[10.6,13.8] | 12.9[7.4,12.9] | 0.341 |
 HbA1c(%)[M(P25,P75)] | 6.8[6.8,6.8] | 7.3[6.8,8.0] | 6.8[6.8,6.8] | 0.002 |
 TC(mmol/L)[M(P25,P75)] | 5.0[4.3,5.8] | 4.6[3.8,6.2] | 5.0[4.3,5.8] | 0.546 |
 TG(mmol/L)[M(P25,P75)] | 1.6[1.2,2.1] | 1.5[1.2,2.9] | 1.6[1.2,2.1] | 0.955 |
 HDL-C(mmol/L)[M(P25,P75)] | 1.2[1.0,1.4] | 0.9[0.8,1.2] | 1.2[1.0,1.4] | 0.035 |
 LDL-C(mmol/L)[M(P25,P75)] | 3.1[2.6,3.7] | 3.2[2.3,4.1] | 3.1[2.6,3.7] | 0.955 |
 HOMAIR[M(P25,P75)] | 3.1[2.2,4.1] | 4.0[3.0,5.8] | 3.1[2.1,4.1] | 0.146 |
 Testosterone(nmol/L)[M(P25,P75)] | 1.3[1.1,1.5] | 1.3[1.3,1.3] | 1.3[1.1,1.5] | 0.912 |
Treatment | ||||
 Surgical approach (n)(%) |  |  |  | 0.079 |
  Open | 73 | 6(75.0) | 67(41.9) |  |
  Minimally invasive | 95 | 2(25.0) | 93(58.1) |  |
 Postoperative chemotherapy (n)(%) |  |  |  | 0.132 |
  No | 108 | 3(37.5) | 105(66.0) |  |
  Yes | 59 | 5(62.5) | 54(34.0) |  |
 Postoperative radiotherapy (n)(%) |  |  |  | 0.438 |
  No | 117 | 7(87.5) | 110(69.2) |  |
  Yes | 50 | 1(12.5) | 49(30.8) |  |
 Postoperative endocrine therapy (n)(%) | ||||
  No | 143 | 5(83.3) | 138(86.3) | 1.000 |
  Yes | 23 | 1(16.7) | 22(13.8) |  |